Ginkgo Bioworks Holdings, Inc. (DNA) came out with a quarterly loss of $1.08 per share versus the Zacks Consensus Estimate of a loss of $2.40. This compares to loss of $3.60 per share a year ago.

Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the ...

Ginkgo Bioworks Holdings, Inc. (DNA) revealed Loss for third quarter that decreased from last year The company's earnings totaled ...

Return on Assets (ROA): Ginkgo Bioworks Holdings's ROA lags behind industry averages, suggesting challenges in maximizing ...

Ginkgo Bioworks (DNA) completed the first milestone of a partnership with Merck (MRK) focused on improving biologic manufacturing. As part of ...

Ginkgo Bioworks Holdings, Inc. , which is building the leading platform for cell programming and biosecurity, today announced its results for the third quarter ended September ...

The below comparison of the analyst ratings and average 1-year price targets of Ecovyst, Rayonier Adv Materials and Ginkgo Bioworks Holdings, three prominent players in the industry, gives insights ...

In this article, we are going to take a look at where Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) stands against other most promising gene editing stocks to buy according to hedge funds. The ...

Presentation and Q&A session scheduled for post-market on Tuesday, November 12, 2024 The presentation details and webcast link will be available on Ginkgo's investor relations website at https ...

Every investor in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) should be aware of the most powerful shareholder groups. The group holding the most number of shares in the company, around 48% to be ...

Ginkgo Bioworks Holdings Inc, based in Boston, Massachusetts, specializes in cell programming to revolutionize the production of various products. By manipulating cells, they create novel ...